Diaceutics (LON:DXRX) Trading 0.7% Higher – What’s Next?

Diaceutics PLC (LON:DXRX)’s stock price rose 0.7% on Wednesday . The company traded as high as GBX 143 and last traded at GBX 143. 67,088 shares were traded during trading, a decline of 68% from the average session volume of 211,010 shares. The stock had previously closed at GBX 142.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, Diaceutics has an average rating of “Buy” and an average price target of GBX 215.

Diaceutics Trading Up 0.7%

The stock has a market capitalization of £121.02 million, a P/E ratio of 1,300.00 and a beta of 0.89. The firm’s 50 day moving average price is GBX 141.76 and its 200 day moving average price is GBX 152.09. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92.

Diaceutics (LON:DXRX) last posted its earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share for the quarter. The company had revenue of GBX 3,844 million during the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. As a group, equities research analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.